Does rosemary oil help with thinning hair? We asked an expert
Rosemary oil packs a punch of natural goodness without a hefty price tag. If you try products like Amazon's Botanic Hearth's 100% Pure Rosemary Oil, you could be giving your hair care routine the makeover it needs. And right now, the hair oil is on sale for 28 per cent off — no wonder more than 10,000 people bought it in the past month.
Scroll down to see what all the buzz is about.
Formulated with pure rosemary extract, this hair oil contains no synthetic additives or harmful chemicals.
If you're on the lookout for a rosemary oil that can rescue you from thinning hair and provide scalp nourishment, Botanic Hearth's product is worth checking out. Botanic Hearth claims that its product is made with pure extract and also includes biotin, jojoba oil and castor oil. It comes with an applicator comb, making it easy to apply directly to your scalp.
⭐️ 4.2/5 stars
💬 9,900+ ratings
🏆 "Works like magic"
The original, full-size bottle has earned more than 13,000 reviews on Amazon and a 4.2-star rating. One person notes 'insane growth after a month,' and another says they saw a noticeable difference within three weeks — it works 'like magic,' they write.
If you're looking for a "natural, affordable solution to support hair growth" and "improve scalp health," then "I highly recommend trying rosemary oil," says another reviewer. With regular use, "it can make a noticeable difference."
"This actually worked!" writes a third shopper. "My bald spot is growing in nicely," they say. "I'm so thankful!"
Several users appreciate the product's quality, mentioning how it leaves hair 'silky and soft,' but they are disappointed about the lack of visible results. Some reviewers cite a 'greasy look' and its ineffectiveness against dandruff, with one person stating it 'makes hair stiff and scalp greasy.'
Caroline Ruggiero, a certified trichologist with the International Association of Trichologists (I.A.T), tells Yahoo Canada that rosemary oil could just be your new best friend, primarily because of its ability to promote 'microcirculation and vasodilation,' both of which have been linked to hair growth. 'Rosemary has anti-fungal properties and stimulating properties. In many cases, rosemary is used in combination with other oils and ingredients to aid in scalp problems,' she says.
Formulated with pure rosemary extract, this hair oil contains no synthetic additives or harmful chemicals.
In cases of natural hair thinning, rosemary oil has shown favourable results. However, Ruggiero, the CEO of Truly You Hair and Scalp Clinic, says that for certain disorders, such as androgenic alopecia (male pattern baldness), which is autoimmune, 'essential oil cannot grow hair back.' She adds, 'Treating most hair loss disorders is like treating aging — there is no cure. But just because there is no cure does not mean there is no care.'
A 2023 study on mice corroborates that rosemary helps promote hair growth. Additionally, Ruggiero recommends combining rosemary oil with other essential oils to enhance its benefits. For strengthening hair, she suggests 'Bay St. Thomas (Pimenta racemosa) and grapefruit oils,' while for revitalizing the scalp, 'rosewood and geranium oils are ideal.'
To improve scalp health and tackle dandruff, Ruggiero advises mixing rosemary oil with palmarosa, cade and laurel oils. 'For a shampoo boost, try adding eight drops of rosemary oil, six of juniper, three of chamomile and eight of lavender. 'This blend can be helpful in treating dandruff,' she says
Thanks to its antimicrobial, antifungal and rubefacient properties, rosemary oil is safe to use on beards. 'These properties could provide potential benefits for beard care,' Ruggiero adds. While rosemary essential oil isn't typically irritating, she emphasizes that it should always be diluted and used for short periods, especially if you have sensitive or damaged skin.
'In high doses, when used internally, it can be toxic,' she warns. Ruggiero also says that folks with epilepsy best avoid rosemary oil. 'Camphor is a constituent in rosemary and can cause convulsions,' she explains.
For those dedicated to their hair care routine, the Botanic Hearth Rosemary Hair Oil could be a good addition, especially considering its sale price. Studies have shown that consistent and long-term use of rosemary oil has supported hair growth and thickening. However, it's important to set realistic expectations. 'Hair loss can be challenging, and it's important to seek professional, evidence-based support to address it effectively," Ruggiero advises.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time Business News
2 hours ago
- Time Business News
Biologics CDMO Surges with Chronic Disease Rise and Innovation Demand
Biologics have made major impact when it comes to tackling the inflammation that causes so much damage to joints and other organs in conditions like arthritis and other inflammatory diseases. Companies specializing in Biologics CDMO, or Contract Development and Manufacturing Organizations, provide crucial services in developing and manufacturing these biological medical products for the pharmaceutical industry. Increasing cases of chronic diseases and growth in ageing population has contributed in market growth. Growing demand for novel therapies and need for huge capital investment for innovative & advanced technologies in pharmaceutical companies is further expected to provide lucrative opportunities in Biologics CDMO domain. Key Growth Drivers and Opportunities Rising Prevalence of Cancer Diseases: Growing prevalence of cancer diseases has become a major factor in Biologics CDMO market growth. Different types of cancer are on the rise due to poor and unhealthy lifestyles. Breast cancer, lung cancer, liver and kidney cancer, and pancreatic cancer are on the rise. For instance, according to Center for Disease and Control and Prevention (CDC), In the United States in 2019, 1,752,735 new cancer cases were reported and 599,589 people died of cancer. Emerging Pharmaceutical and Biotech Companies: Increasing need for CDMOs from emerging pharmaceutical and biotech companies has boosted the target market's growth. The rise in the number of clinical trials has become a major driver of target market expansion. According to Food and Drug Administration (FDA) there are around 50 ongoing clinical trials in cell and gene therapy by major and emerging biotech or pharmaceutical companies. Challenges There are several challenges faced by CDMOs, are cost pressure, fierce competition, consolidation, and constant technological innovations, which may hamper the market growth. The wrong innovative CDMO solution provider may lead to a bad customer experience and variations in the standards of customer service may lead to quality problems. Moreover, this may also lead to less control over the production process, which act as a challenges and disadvantages of CDMOs which in turn hampered the demand for Biologics CDMO Innovation and Expansion Samsung Wins USD 183 Mn Pfizer Vaccine Deal In March 2023, Samsung Biologics signed a deal Pfizer to manufacture COVID-19 vaccines for Moderna. The value of the contract is USD 183 million and will run through the year 2029. This new deal worth 15% of Samsung's USD 1.2 billion revenue from 2021 year. Given initiative shows how much Samsung Biologics is stepping up as a top player in the global CDMO scene. It also makes Pfizer's supply chain much more robust when it comes to mRNA vaccines. Plus, this long-term partnership is a clear sign that both companies are committed to being ready for future pandemics. Lonza Invests $518M in Swiss Biologics Expansion In July 2022, Lonza has planned to spend USD 518 million on a large-scale fill-finish manufacturing plant in Stein, Switzerland. This new facility is set to greatly enhance Lonza's capabilities in making sterile drug products. It's specifically built to meet the growing demand for complex biologics and advanced therapies. This investment further strengthens Switzerland's reputation as a global leader in the biopharmaceutical sector. Inventive Sparks, Expanding Markets The key players operating the biologics CDMO market includes, Lonza Group, Catalent Inc., Samsung Biologics, Eurofins Scientific, Boehringer Ingelheim Group, FUJIFILM Diosynth Biotechnologies Inc., among others. Biologics CDMO companies are all about speeding up the process of creating new drugs, making sure that high-quality manufacturing can easily expand to meet demand for complex treatments. Their main goals are to foster innovation, improve efficiency, and help make healthcare accessible worldwide. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
%3Amax_bytes(150000)%3Astrip_icc()%2Ftal-brooks-ghost-max-2-sale-one-off-tout-c70b169b44e64270a1cd6c2d4dd23aba.jpg&w=3840&q=100)

Travel + Leisure
6 hours ago
- Travel + Leisure
These Brooks Shoes Are Approved by Podiatrists, Disney-goers, and Nurses—and They're on Rare Sale
It's peak travel season, which means my calendar is booked with 'out of office' time and my online shopping cart is full of vacation essentials. Since my upcoming itineraries include plenty of sightseeing, I've been hunting for comfortable walking shoes—and I just found an unbeatable deal on highly rated Brooks sneakers. Brooks just marked down one of its comfiest sneakers, the Ghost Max 2 Running Shoe, in every single color. These shoes are podiatrist-approved and have garnered thousands of five-star ratings across various retailers. They're 27 percent off and selling quickly, so be sure to snag a pair while the deal lasts. $150 $110 at Amazon $150 $110 at Zappos $150 $110 at The Brooks Ghost Max 2 Running Shoes have a thick, cushiony sole that's ideal for logging thousands of steps while sightseeing. The generously cushioned, rounded sole rocks you from heel to toe, turning each step into a smooth glide. Plus, the sole has a broad base to maximize stability. Don't just take it from us, though: These shoes have earned a Seal of Acceptance from the American Podiatric Medical Association, an award reserved for shoes that best protect foot health. Reviewers are raving about the comfort offered by these sneakers. One shopper wrote they have had 'two knee replacements, a hip issue, and chronic plantar fasciitis,' and after a year of shopping for comfortable sneakers, finally landed on these Ghost Max 2s. After purchasing their first pair, they immediately ordered a second. Another shopper, who works on their feet all day, wrote that they were dealing with ankle pain for weeks before switching to these sneakers. After a few days of the Ghost Max 2s, they 'felt such a relief.' Peruse the reviews yourself and you'll find hundreds of shoppers who swear by these walking shoes. Whether they're racking up tens of thousands of steps at Disney or working 12-hour hospital shifts as a nurse, reviewers love these sneakers' comfort and support. $150 $110 at Amazon $150 $110 at Zappos $150 $110 at Best of all, these sneakers come in a wide variety of colors to suit every style. My favorites include an all-white option, a pastel purple pair, and a versatile black version. Plus, these sneakers are equally marked down in men's sizes. Some colors are selling out quickly, so be sure to act fast—or keep scrolling to shop even more comfy, travel-ready sneakers from $75. Love a great deal? Sign up for our T+L Recommends newsletter and we'll send you our favorite travel products each week.


Business Upturn
16 hours ago
- Business Upturn
Heartflow Plaque Analysis to be Covered by UnitedHealthcare Plans Nationwide
MOUNTAIN VIEW, Calif., July 22, 2025 (GLOBE NEWSWIRE) — Heartflow, Inc. , the leader in AI technology for coronary artery disease (CAD), today announced Heartflow Plaque Analysis will be covered by UnitedHealthcare across all lines of business, including Commercial, Medicare Advantage, and Community plans. UnitedHealthcare is the first insurer to update its policies to cover Heartflow Plaque Analysis to fully align with the guidelines recently issued by radiology benefit manager EviCore. 'UnitedHealthcare's decision to cover Heartflow Plaque Analysis nationwide is a tremendous step in advancing patient access to our proven AI-driven plaque technology,' said John Farquhar, President and CEO of Heartflow. 'We are pleased that this major commercial payer recognizes the innovation and value that Heartflow's technology can provide to its members and healthcare providers in diagnosing and managing coronary artery disease. This decision will increase access for early detection and quantification of plaque using our precision Plaque Analysis tool, setting a new standard for cardiovascular care coverage.' The updated coverage will become effective October 1, 2025 for patients with acute or stable chest pain and mild-to-moderate narrowing of coronary arteries (1-70% stenosis) found on coronary computed tomography angiography (CCTA). Expanded access will allow for greater adoption of Heartflow Plaque Analysis for clinicians to incorporate into their diagnostic and patient management protocols, delivering more personalized treatment. Heartflow Plaque Analysis is the only FDA-cleared, AI-enabled, noninvasive plaque quantification tool with a reported 95% agreement with the gold standard, IVUS, in a prospective, global trial using blinded core lab adjudication.1 It is proven to change medical management in over half of patients beyond CCTA alone, helping physicians to improve outcomes.2 This coverage milestone follows the recent presentation of clinical outcomes from the DECIDE registry, which found management changes informed by Heartflow Plaque Analysis led to an average LDL cholesterol decrease of 18.7mg/dL.3 This clinically significant reduction is associated with an estimated 15% decrease in the risk of a cardiac event, highlighting the potential of Heartflow Plaque Analysis to improve patient outcomes by guiding more effective medical therapy and interventions.4 Heartflow is dedicated to transforming CAD from the leading cause of death to a disease that can be proactively managed for life. In the United States, CAD is estimated to be responsible for one heart attack every 40 seconds and one out of every five deaths.5 Heartflow has been adopted by more than 1,400 institutions globally and continues to strengthen its commercial presence to make this cutting-edge solution more widely available to an increasingly diverse patient population worldwide. About Heartflow, Inc. Heartflow is advancing coronary care by transforming coronary artery disease into a screenable, diagnosable, and manageable condition. Heartflow One is the only complete, non-invasive, precision coronary care platform providing patient insights throughout the guideline-directed CCTA pathway. The AI-driven platform — including Roadmap™ Analysis , FFR CT Analysis and Plaque Analysis — is supported by the ACC/AHA Chest Pain Guideline and backed by more than 600 peer-reviewed publications. Heartflow has helped clinicians manage over 400,000 patients worldwide. Discover how we're shaping the future of cardiovascular care at . Media Contact Elliot Levy [email protected]